Center-Authored Papers

Filters: Author is Carducci, Michael A  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Y
Yu EY, Massard C, Gross ME, Carducci MA, Culine S, Hudes G, Posadas EM, Sternberg CN, Wilding G, Trudel GC et al..  2011.  Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.. Urology. 77(5):1166-71. Abstract
S
Sonpavde G, Pond GR, Plets M, Tangen CM, Hussain MHA, Lara PN, Goldkorn A, Garzotto MG, Mack PC, Higano CS et al..  2017.  Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421.. Clinical genitourinary cancer. Abstract
Schweizer MT, Wang H, Luber B, Nadal R, Spitz A, Rosen MD, Cao H, Antonarakis ES, Eisenberger MA, Carducci MA et al..  2016.  Bipolar androgen therapy for men with androgen ablation naïve prostate cancer: Results from the phase II BATMAN study.. The Prostate. 76(13):1218-1226. Abstract
Schweizer MT, Antonarakis ES, Wang H, Ajiboye SA, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA et al..  2015.  Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study.. Science translational medicine. 7(269):269ra2. Abstract
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN et al..  2016.  Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
Q
Quinn DI, Tangen CM, Hussain M, Lara PN, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk PJ et al..  2013.  Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.. The lancet oncology. 14(9):893-900. Abstract
M
Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Buyyounouski MK, Carducci MA, Chang SS, Choueiri TK, Gupta S et al..  2012.  Testicular cancer.. Journal of the National Comprehensive Cancer Network : JNCCN. 10(4):502-35.
Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL et al..  2009.  NCCN clinical practice guidelines in oncology: testicular cancer.. Journal of the National Comprehensive Cancer Network : JNCCN. 7(6):672-93.
Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL et al..  2009.  NCCN clinical practice guidelines in oncology: kidney cancer.. Journal of the National Comprehensive Cancer Network : JNCCN. 7(6):618-30.
Motzer RJ, Agarwal N, Beard C, Bhayani S, Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes GR et al..  2011.  Kidney cancer.. Journal of the National Comprehensive Cancer Network : JNCCN. 9(9):960-77.
G
Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA et al..  2014.  Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. Abstract
A
Antonarakis ES, Heath EI, Posadas EM, Yu EY, Harrison MR, Bruce JY, Cho SY, Wilding GE, Fetterly GJ, Hangauer DG et al..  2013.  A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.. Cancer chemotherapy and pharmacology. Abstract